Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UK Biobank gets unanimous backing from international experts after piloting phase

22.08.2006
Multi-million pound project to go national from end of 2006

UK Biobank – the multi-million pound visionary medical project aimed at improving the prevention, diagnosis and treatment of a wide range of diseases that kill, disable or cause widespread misery (such as cancer, heart disease, diabetes, dementia, mental illness, joint disease and many other debilitating conditions) – announced today (Tuesday 22 August) that it has received the go-ahead to roll out its programme nationwide.

Following a three-month piloting phase in the Manchester area, the final protocol received unanimous backing from a team of international scientific and medical experts, and from the project’s funders.

The success of the 3,800-participant piloting phase means that, around the end of this year, letters will start going out to men and women aged 40 to 69, who will be invited to attend one of a network of assessment centres[1] to be set up in locations all around the UK. The aim is to recruit half a million people – nearly one percent of the British population – over the next four years.

UK Biobank will gather, store and protect a vast bank of medical data and material that will allow researchers to study in depth, in decades to come, how the complex interplay of genes, lifestyle and environment affects our risk of disease. It is the first time that such a project has been attempted in such fine detail on such a vast scale.

The final protocol for the £61m project, which is being funded by the Medical Research Council (MRC), the Wellcome Trust, the Department of Health, the Scottish Executive and the North West Regional Development Agency has been subjected to rigorous and detailed scrutiny by an independent International Review Panel set up by the funders.

In its report, the panel concluded that: “UK Biobank has the potential, in ways that are not currently available elsewhere, to support a wide range of research, particularly investigations into complex interactions of various exposures, including genetic and lifestyle factors in the pathways to disease and health.” The panel were impressed with the level of detailed planning and piloting that had gone into the development of the protocol, and considered it to be one of the most fully developed protocols they had seen. UK Biobank was also found to have set new standards for automated blood sample processing and storage, supplemented by a sophisticated computerised system to track samples. The panel said the approach to ethical oversight and governance of the resource was “exemplary and would be held up as a gold standard across the world”.

The panel’s overall view was that “UK Biobank is a unique opportunity to build an amazingly rich resource with a range of endpoints for future research that justified the initial establishment costs.”

Professor Rory Collins, UK Biobank’s Principal Investigator said: “Clearly, everyone at UK Biobank is delighted with the support and enthusiasm that this unique public health project has received from the funders and, in particular, from the eminent independent experts who scrutinised every detail of our protocol and plans. We are also grateful for their ideas for adding value to the resource, which we are already starting to implement and will be exploring further with the many scientists already involved in UK Biobank, as well as with other international experts. In addition, we have established an independent International Scientific Advisory Board to help us develop the resource during the years to come. We will constantly review everything we do so as to maximise recruitment of the widest possible cross-section of the population, to improve the quality of the health-related information that is obtained, to inform participants and the public about our progress, and to uphold the highest scientific and ethical standards throughout. For decades to come, the UK Biobank resource should provide researchers around the world with vital insights into some of the most distressing diseases of middle and old age.”

The chairman of the International Review Panel, Professor Thorkild Sørensen, from the Institute of Preventive Medicine in Copenhagen, Denmark, said: “It was a great honour to chair the panel for this exciting and very important project. Comprehensive and impressive plans, based on valuable pilot studies, were presented to the panel, who unanimously endorsed the protocol and put forward a number of suggestions that would enhance the long-term value of this unique project.”

Dr Adrian Mercer, Chief Executive of South Manchester NHS Primary Care Trust – the first PCT to participate in the piloting phase – said: “The project was successfully launched in Manchester, being well received by those invited to take part and supported by PCTs and clinicians. I am sure the roll-out nationally will be equally successful.”

Professor Colin Blakemore, Chief Executive of the Medical Research Council said: “UK Biobank offers enormous potential to find out more about the complex links between our genes, the lives we lead and our health. The Medical Research Council is delighted to continue to fund this project, which will provide scientists with extraordinary information and will offer unprecedented opportunities to improve people’s lives. The project, under the leadership of Rory Collins, is already helping researchers by pioneering new ways to gather and collate large quantities of information. Over the coming years the data from this study will grow into a unique resource for future generations.”

Dr. Mark Walport, Director of the Wellcome Trust said: “The piloting of UK Biobank has gone extremely well. The funders, advised by international peer reviewers, were very impressed by the leadership of Rory Collins and his team and by their plans for the future implementation of UK Biobank. I am delighted that we have agreed full funding for the programme and that large-scale recruitment will start shortly. UK Biobank, already watched with envy by researchers across the world, will provide a remarkable resource, allowing us to answer important questions about health and disease. This study has the opportunity to make a real difference to the health of future generations.”

Margaret Willson | alfa
Further information:
http://www.mwcommunications.org.uk

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>